Healthcare
InterCure Ltd.(INCR)
Live Price
Offline$0.929
-1.06% today
1Y Change
-37.65%
Window
Jun 26, 2025 โ Jun 18, 2026
- Market Cap
- $140.00M
- Revenue Growth
- -32.8%
- EPS Growth
- -4.4%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 26, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
InterCure Ltd. (INCR) is a Healthcare stock with a market cap of $140.00M and listed on NASDAQ. The stock last traded around $0.93 and down 37.7% across the available one-year price window (Jun 26, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -32.8%, EPS growth of -4.4%, a dividend yield of 0.0%. What stands out right now is revenue -32.8%, EPS -4.4%, free cash flow -26.8% with operating margin -17.8% and ROIC -4.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines INCR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-32.8% vs +7.6% peer median
Operating Margin
Below sector median
-17.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -32.8% and EPS is at -4.4%, with operating margin around -17.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +3.8% | +8.0% | +31.9% |
2025 Sep 1, 2025 | โ | -1.2% | -1.8% | +0.6% |
2025 Aug 20, 2025 | โ | +2.5% | +0.0% | -8.5% |
Benchmark Edge
INCR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INCR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INCR Max Drawdown
-57.80%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INCR and SPY.
Company Overview
InterCure Ltd.
NASDAQ Global Market
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.
- Leadership
- Alexander Rabinovich
- IPO Date
- Jan 28, 2019
- Employees
- 320
- Street Address
- 85 Medinat ha-Yehudim Street
- Mailing
- Herzliya, 4676670
- Region
- Herzliya, IL
- Reporting Currency
- USD
- Investor Line
- 972 7 7460 5012
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.7
- Price/Book
- 0.3
Growth
- Revenue
- -32.8%
- EPS
- -4.4%
- Free Cash Flow
- -26.8%
Profitability
- Gross Margin
- 21.7%
- Operating Margin
- -17.8%
- Net Margin
- -19.5%
- ROE
- -8.7%
- ROIC
- -4.5%
Balance Sheet
- Debt/Equity
- 0.42
- Current Ratio
- 1.85
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.